This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.SiegelRLMillerKDJemalA.Cancer statistics, 201520156552910.3322/caac.21254Search in Google Scholar
Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):694-705.GroomePABolejackVCrowleyJJKennedyCKrasnikMSobinLHet alThe IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours20072869470510.1097/JTO.0b013e31812d05d5Search in Google Scholar
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-46.RosellRCarcerenyEGervaisRVergnenegreAMassutiBFelipet alErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial20121332394610.1016/S1470-2045(11)70393-XSearch in Google Scholar
Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141-51.YangJCWuYLSchulerMSebastianMPopatSYamamotoNet alAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials20151621415110.1016/S1470-2045(14)71173-8Search in Google Scholar
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57.MokTSWuYLThongprasertSYangCHChuDTSaijoNet alGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma2009361109475710.1056/NEJMoa081069919692680Search in Google Scholar
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-77.SolomonBJMokTKimDWWuYLNakagawaKMekhailTet alFirst-line crizotinib versus chemotherapy in ALK-positive lung cancer20143712321677710.1056/NEJMoa140844025470694Search in Google Scholar
Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963-71.ShawATOuSHBangYJCamidgeDRSolomonBJSalgiaRet alCrizotinib in ROS1-rearranged non-small-cell lung cancer20143712119637110.1056/NEJMoa1406766426452725264305Search in Google Scholar
Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE et al. Phase III trial of irinotecan/ cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530-5.LaraPNJrNataleRCrowleyJLenzHJRedmanMWCarletonJEet alPhase III trial of irinotecan/ cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124200927152530510.1200/JCO.2008.20.1061268485519349543Search in Google Scholar
Niell HB, Herndon JE 2nd, Miller AA, Watson DM, Sandler AB, Kelly K et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005;23(16):3752-9.NiellHBHerndonJE2ndMillerAAWatsonDMSandlerABKellyKet alRandomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732200523163752910.1200/JCO.2005.09.07115923572Search in Google Scholar
Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol. 2002;20(19):3947-55.ArdizzoniATjan-HeijnenVCPostmusPEBuchholzEBiesmaBKarnicka-MlodkowskaHet alStandard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-089232002201939475510.1200/JCO.2002.02.06912351591Search in Google Scholar
Blank C, Mackensen A. Contribution of the PD-L1/ PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739-45.BlankCMackensenA.Contribution of the PD-L1/ PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion20075657394510.1007/s00262-006-0272-1Search in Google Scholar
Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20.WolchokJDHoosAO’DaySWeberJSHamidOLebbéCet alGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria2009152374122010.1158/1078-0432.CCR-09-1624Search in Google Scholar
Opdivo prescribing information. Last accessed December 13 2015 from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125527s000lbl.pdfLast accessed December 13 2015 fromhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125527s000lbl.pdfSearch in Google Scholar
Opdivo prescribing information. Last accessed January 2 2016 from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001 876.jsp&mid=WC0b01ac058001d124Last accessed January 2 2016 fromhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001 876.jsp&mid=WC0b01ac058001d124Search in Google Scholar
Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33(18):2004-12.GettingerSNHornLGandhiLSpigelDRAntoniaSJRizviNAet alOverall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer2015331820041210.1200/JCO.2014.58.3708Search in Google Scholar
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257-65.RizviNAMazièresJPlanchardDStinchcombeTEDyGKAntoniaSJet alActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial20151632576510.1016/S1470-2045(15)70054-9Search in Google Scholar
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35.BrahmerJReckampKLBaasPCrinòLEberhardtWEPoddubskayaEet alNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer201537321233510.1056/NEJMoa1504627468140026028407Search in Google Scholar
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627-39.BorghaeiHPaz-AresLHornLSpigelDRSteinsMReadyNEet alNivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer20153731716273910.1056/NEJMoa1507643570593626412456Search in Google Scholar
Horn L, Brahmer J, Reck M, Borghaei H, Spigel D, Steins M et al. Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous non-small cell lung cancer: Subgroup analyses and patient reported outcomes. Ann Oncol 2015;26:ix125HornLBrahmerJReckMBorghaeiHSpigelDSteinsMet alPhase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous non-small cell lung cancer: Subgroup analyses and patient reported outcomes201526ix12510.1093/annonc/mdv532.01Search in Google Scholar
Gettinger S, Shepherd F, Antonia S, Brahmer J, Chow L, Juergens R et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol. 2014;32:abstr 8024GettingerSShepherdFAntoniaSBrahmerJChowLJuergensRet alFirst-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 status201432abstr 802410.1200/jco.2014.32.15_suppl.8024Search in Google Scholar
Antonia S, Brahmer J, Gettinger S, Chow L, Juergens R, Shepherd F et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (Pt-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32:abstr 8113AntoniaSBrahmerJGettingerSChowLJuergensRShepherdFet alNivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (Pt-DC) in advanced non-small cell lung cancer (NSCLC)201432abstr 811310.1200/jco.2014.32.15_suppl.8113Search in Google Scholar
Rizvi N, Gettinger S, Goldman J, Hellmann M, Chow L, Juergens R et al. Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC). WCLC 2015 September 6-9 2015, ORAL02.05RizviNGettingerSGoldmanJHellmannMChowLJuergensRet alWCLC 2015 September 6-9 2015, ORAL02.05Search in Google Scholar
Rizvi N, Chow L, Borghaei H, Shen Y, Harbison C, Alaparthy S et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR Mt) advanced NSCLC. J Clin Oncol. 2014;32:abstr 8022.RizviNChowLBorghaeiHShenYHarbisonCAlaparthySet alSafety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR Mt) advanced NSCLC201432abstr 802210.1200/jco.2014.32.15_suppl.8022Search in Google Scholar
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23-34.LarkinJChiarion-SileniVGonzalezRGrobJJCoweyCLLaoCDet alCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma20153731233410.1056/NEJMoa1504030Search in Google Scholar
Keytruda prescribing information. Last accessed December 13 2015 from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s005lbl.pdfLast accessed December 13 2015 fromhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s005lbl.pdfSearch in Google Scholar
Keytruda prescribing information. Last accessed December 13 2015 from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp&mid=WC0b01ac058001d124Last accessed December 13 2015 fromhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp&mid=WC0b01ac058001d124Search in Google Scholar
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.GaronEBRizviNAHuiRLeighlNBalmanoukianASEderJPet alPembrolizumab for the treatment of non-small-cell lung cancer20153722120182810.1056/NEJMoa1501824Search in Google Scholar
Hellmann M, Garon E, Gandhi L, Hui R, Zhang J, Rangwala R et al. Efficacy of Pembrolizumab in Key Subgroups of Patients with Advanced NSCLC. WCLC 2015 September 6-9 2015, MINI03.05HellmannMGaronEGandhiLHuiRZhangJRangwalaRet alWCLC 2015 September 6-9 2015, MINI03.05Search in Google Scholar
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015 Dec 18; [Epub ahead of print]HerbstRSBaasPKimDWFelipEPérez-GraciaJLHanJYet alPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial2015Dec18[Epub ahead of print]10.1016/S0140-6736(15)01281-7Search in Google Scholar
Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419-25.SperdutoPWKasedNRobergeDXuZShanleyRLuoXet alSummary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases20123044192510.1200/JCO.2011.38.0527Search in Google Scholar
Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, Moore B et al. Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061). J Clin Oncol. 2015;33:abstr 8005.MulvennaPNankivellMBartonRFaivre-FinnCWilsonPMooreBet alWhole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061)201533abstr 800510.1200/jco.2015.33.15_suppl.8005Search in Google Scholar
Goldberg S, Gettinger S, Mahajan A, Herbst R, Chiang A, Tsiouris J et al. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. J Clin Oncol. 2015;33:abstr 8035.GoldbergSGettingerSMahajanAHerbstRChiangATsiourisJet alActivity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases201533abstr 803510.1200/jco.2015.33.15_suppl.8035Search in Google Scholar
Besse B, Johnson M, Janne P, Garassino M, Eberhardt W, Peters S et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). ECC 2015 September 25-29 2015, LBA 16BesseBJohnsonMJannePGarassinoMEberhardtWPetersSet alECC 2015 September 25-29 2015, LBA 1610.1016/S0959-8049(16)31938-4Search in Google Scholar
Vansteenkiste J, Fehrenbacher L, Spira A, Mazieres J, Park K, Smith D et al. Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). ECC 2015 September 25-29 2015, LBA 14VansteenkisteJFehrenbacherLSpiraAMazieresJParkKSmithDet alECC 2015 September 25-29 2015, LBA 1410.1016/S0959-8049(15)30072-1Search in Google Scholar
Camidge R, Liu S, Powderly J, Ready N, Hodi S, Gettinger S et al. Atezolizumab (MPDL3280A) Combined with Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC): A Phase Ib Safety and Efficacy Update. WCLC 2015 September 6-9 2015, ORAL02.07CamidgeRLiuSPowderlyJReadyNHodiSGettingerSet alWCLC 2015 September 6-9 2015, ORAL02.07Search in Google Scholar
Rizvi N, Brahmer J, Ou SH, Segal NH, Khleif S, Hwu WJ et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33:abstr 8032.RizviNBrahmerJOuSHSegalNHKhleifSHwuWJet alSafety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)201533abstr 803210.1200/jco.2015.33.15_suppl.8032Search in Google Scholar
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65.BrahmerJRTykodiSSChowLQHwuWJTopalianSLHwuPet alSafety and activity of anti-PD-L1 antibody in patients with advanced cancer20123662624556510.1056/NEJMoa1200694356326322658128Search in Google Scholar
Rizvi N, Chaft J, Balmanoukian A, Goldberg S, Sanborn R, Steele K et al. Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status. J Immunother Cancer. 2015;3:P193.RizviNChaftJBalmanoukianAGoldbergSSanbornRSteeleKet alTumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status20153P19310.1186/2051-1426-3-S2-P193Search in Google Scholar
Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847-56.PatelSPKurzrockR.PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy20151448475610.1158/1535-7163.MCT-14-0983Search in Google Scholar
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.LeDTUramJNWangHBartlettBRKemberlingHEyringADet alPD-1 Blockade in Tumors with Mismatch-Repair Deficiency20153722625092010.1056/NEJMoa1500596Search in Google Scholar
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187-99.BradleyJDPaulusRKomakiRMastersGBlumenscheinGSchildSet alStandard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study20151621879910.1016/S1470-2045(14)71207-0Search in Google Scholar
Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007;25(13):1698-704.VokesEEHerndonJE2ndKelleyMJCicchettiMGRamnathNNeillHet alInduction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B20072513169870410.1200/JCO.2006.07.356917404369Search in Google Scholar
Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol. 2012;23(7):1730-8.JalalSIRiggsHDMelnykARichardsDAgarwalaANeubauerMet alUpdated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology20122371730810.1093/annonc/mdr56522156624Search in Google Scholar
Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC et al. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660-6.AhnJSAhnYCKimJHLeeCGChoEKLeeKCet alMultinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04201533242660610.1200/JCO.2014.60.013026150444Search in Google Scholar
Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-31.PostowMACallahanMKBarkerCAYamadaYYuanJKitanoSet alImmunologic correlates of the abscopal effect in a patient with melanoma2012366109253110.1056/NEJMoa1112824334520622397654Search in Google Scholar
Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712-20.GibneyGTKudchadkarRRDeContiRCThebeauMSCzuprynMPTettehLet alSafety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma20152147122010.1158/1078-0432.CCR-14-2468462068425524312Search in Google Scholar
Stewart TJ, Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol. 2007;179(5):2851-9.StewartTJAbramsSI.Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth200717952851910.4049/jimmunol.179.5.285117709499Search in Google Scholar
Carrizosa DR, Gold KA. New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2015;4(5):553-9.CarrizosaDRGoldKA.New strategies in immunotherapy for non-small cell lung cancer2015455539Search in Google Scholar
Agra Y, Pelayo M, Sacristan M, Sacristán A, Serra C, Bonfill X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev. 2003;(4):CD001990.AgraYPelayoMSacristanMSacristánASerraCBonfillX.Chemotherapy versus best supportive care for extensive small cell lung cancer20034CD001990Search in Google Scholar
Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20(24):4665-72.SundstrømSBremnesRMKaasaSAasebøUHatlevollRDahleRet alCisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up2002202446657210.1200/JCO.2002.12.111Search in Google Scholar
O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441-7.O’BrienMECiuleanuTETsekovHShparykYCuceviâBJuhaszGet alPhase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer200624345441710.1200/JCO.2006.06.5821Search in Google Scholar
von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658-67.von PawelJSchillerJHShepherdFAFieldsSZKleisbauerJPChryssonNGet alTopotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer19991726586710.1200/JCO.1999.17.2.658Search in Google Scholar
Antonia S, Bendell J, Taylor MH, Calvo E, Jaeger D, De Braud F et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol. 2015;33:abstr 7503.AntoniaSBendellJTaylorMHCalvoEJaegerDDe BraudFet alPhase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032201533abstr 750310.1200/jco.2015.33.15_suppl.7503Search in Google Scholar
Ott PA, Fernandez ME, Hiret S, Kim DW, Moss RA, Winser T et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol. 2015;33:abstr 7502.OttPAFernandezMEHiretSKimDWMossRAWinserTet alPembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028201533abstr 750210.1200/jco.2015.33.15_suppl.7502Search in Google Scholar
Kennedy BJ. The snail’s pace of lung carcinoma chemotherapy. Cancer. 1998;82(5):801-3.KennedyBJ.The snail’s pace of lung carcinoma chemotherapy1998825801310.1002/(SICI)1097-0142(19980301)82:5<801::AID-CNCR1>3.0.CO;2-MSearch in Google Scholar